MedTrace Logo

One Year Pacing Dependency After TAVR

NCT06756282 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2025-01-03

No results posted yet for this study

Summary

Pace maker implantation after the procedure of TAVR can be estimated at 15% of patients. However, some studies have shown that the conduction disturbances after TAVR could resolve over time, and that roughly between one- and two-thirds of patients who required a permanent pace maker implantation post TAVR were not found to be dependent at subsequent follow-up. This study aims to evaluate a cohort of patients permanently implanted with a pacemaker post-TAVR for high-grade conductive disorders and to describe the prevalence of effective pacemaker stimulation at 1 year follow-up. Secondary objectives include the evaluation of the prevalence of effective stimulation 3 months after implantation of the pace maker , description of the types of conductive disorders associated with atrial and/or ventricular stimulation, description of the initial indication for pacemaker implantation, description of the characteristics of the population with or without stimulation dependency. The objective is to better rationalize indication of permanent stimulation after TAVI

Conditions

  • Patients Above 18 Years
  • Patient Discharge
  • Pacing Therapy
  • Aortic Stenosis (Treated With TAVI)

Interventions

PROCEDURE

Pacemaker and defibrillator

only patients with pacemaker implantation will be evaluated in the study

Sponsors & Collaborators

  • Biotronik France

    collaborator INDUSTRY

  • University Hospital, Montpellier

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-13
Primary Completion
2025-10-31
Completion
2027-10-13

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06756282 on ClinicalTrials.gov